Back

Cardioprotective effects of PCSK9 inhibitor evolocumab against doxorubicin-trastuzumab sequential treatments and ipilimumab-induced cardiotoxicity: the role of MyD88/NF-KB/mTORC1 pathways

1 September 2020 (08:30 - 08:30)
Organised by:
Congress Presentation Part of: Cardio-oncology Cardio-Oncology ESC Premium Access ESC Congress 2020

About the speaker

Photo
Doctor Vincenzo Quagliariello

National Cancer Institute G.Pascale Foundation IRCCS, Naples (Italy)

5 More presentations in this session

Presentation thumbnail
Echocardiography for the 10-year prediction of cardiomyopathy in long-term survivors of childhood cancer
Mr J. Leerink (Amsterdam, NL)
Abstract Slides
Presentation thumbnail
Tumor necrosis factor alpha blockade prevents immune checkpoint inhibitor therapy-related cardiotoxicity
Doctor L. Michel (Essen, DE)
Abstract Slides
Presentation thumbnail
Tamponade during immune checkpoint inhibitors therapy in lung cancer: case-reports and systematic review of the literature
Doctor H. Mustafic (Paris, FR)
Abstract Slides
Presentation thumbnail
SGLT2 inhibitor dapagliflozin against anthracycline and trastuzumab-induced cardiotoxicity: the role of MYD88, NLRP3, Leukotrienes/Interleukin 6 axis and mTORC1 /Fox01/3a mediated apoptosis
Doctor V. Quagliariello (Naples, IT)
Abstract Slides
Presentation thumbnail
Cardiovascular risk factors during cancer treatment: prevalence, incidence and prognostic relevance.
Mr J. Caro Codon (Madrid, ES)
Abstract Slides

Access the full session

Session thumbnail
Cardio-oncology

The Event

Event poster

ESC Congress 2020

1 September 2020 08:30 CET
You may be interested in
thumbnail
Congress Presentation
GLP1-RA associated with PCSK9i as chemosensitizing method and therapy of anthracycline-induced cardiotoxicity under exposure to Ox-LDL: biochemical and preclinical evidences
20 June 2025
thumbnail
Congress Presentation
Immune checkpoint inhibition with PD-1 inhibitor induces cardiac dysfunction without overt myocarditis in C57BL/6J mice
29 April 2022
thumbnail
Congress Presentation
Indirect comparison of the safety and efficacy of alirocumab and evolocumab: from a comprehensive meta-analysis of 30 randomized controlled trials
3 September 2019
thumbnail
Congress Presentation
The effect of proprotein convertase subtilisin/kexin type 9 inhibition on the plasma proteome: a SPIRE sub-study
28 August 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources